Biotech Investments
Biotech Investments Ltd is a company dedicated to providing insights, news, and analysis on the biotech and pharmaceutical industry. They offer asset ratings, market news, and updates on various biotech companies and innovations, aiming to discover tomorrow’s blockbusters today. The company actively tracks and reports on significant milestones, clinical trial progress, and corporate developments within the biotech sector.
Industries
Nr. of Employees
small (1-50)
Biotech Investments
France and United States
Products
Orthopedic trauma fixation implant systems
Anatomical plate systems and cannulated screws for treatment of fractures, engineered for specific bone segments with variable-angle fixation options.
Antibacterial surface-treated implant (clinical evaluation)
Orthopedic implant employing an antibacterial surface treatment under human clinical evaluation intended to reduce infection-related complications in trauma implants.
Magnesium-based bioresorbable implant materials (development)
Development-stage magnesium-based implants intended to provide resorbable fixation solutions in trauma applications to reduce need for secondary removal surgery.
Recombinant inhaled alpha-1 antitrypsin candidate (development-stage)
Recombinant alpha-1 antitrypsin formulated for inhalation to deliver therapeutic protein directly to the lungs; preclinical proof-of-principle demonstrated in inflammatory lung disease models and being prepared for clinical proof-of-concept trials.
Inhalation device and protein nebulization technology (device development)
Inhaler and nebulizer device designs optimized for administration of protein therapeutics, developed for compatibility with recombinant inhaled formulations and industrial manufacturing.
Oral small-molecule immunomodulator candidate (development-stage)
Development-stage orally administered small-molecule immunomodulator for treatment of ulcerative colitis and related chronic inflammatory diseases; currently in a pivotal Phase 3 program with ongoing enrollment and planned readouts tied to potential regulatory submission.
Orthopedic trauma fixation implant systems
Anatomical plate systems and cannulated screws for treatment of fractures, engineered for specific bone segments with variable-angle fixation options.
Antibacterial surface-treated implant (clinical evaluation)
Orthopedic implant employing an antibacterial surface treatment under human clinical evaluation intended to reduce infection-related complications in trauma implants.
Magnesium-based bioresorbable implant materials (development)
Development-stage magnesium-based implants intended to provide resorbable fixation solutions in trauma applications to reduce need for secondary removal surgery.
Recombinant inhaled alpha-1 antitrypsin candidate (development-stage)
Recombinant alpha-1 antitrypsin formulated for inhalation to deliver therapeutic protein directly to the lungs; preclinical proof-of-principle demonstrated in inflammatory lung disease models and being prepared for clinical proof-of-concept trials.
Inhalation device and protein nebulization technology (device development)
Inhaler and nebulizer device designs optimized for administration of protein therapeutics, developed for compatibility with recombinant inhaled formulations and industrial manufacturing.
Oral small-molecule immunomodulator candidate (development-stage)
Development-stage orally administered small-molecule immunomodulator for treatment of ulcerative colitis and related chronic inflammatory diseases; currently in a pivotal Phase 3 program with ongoing enrollment and planned readouts tied to potential regulatory submission.
Services
On-demand and scheduled asset-rating reports, competitive landscaping, second-opinion due diligence and expert medical opinions for investors.
Co-development of inhaler and nebulizer devices for administration of protein therapeutics, including integration of nebulization technology and transfer to industrial manufacturing capacity.
Outsourced development of industrial production processes for recombinant proteins, including analytical method development, upstream process optimization, technology transfer and cGMP manufacturing support through clinical and commercial scale-up.
End-to-end services covering preclinical proof-of-principle, IND-enabling study design, clinical trial preparation and regulatory submission support aimed at progressing candidates into proof-of-concept clinical trials.
Access to a network of scientific and clinical advisors in pulmonology, virology and aerosol medicine to inform translational strategy, target selection and trial design.
Preclinical testing services using lung-on-chip microphysiological systems combined with computational pulmonary distribution and aerosol deposition simulations to generate human-relevant safety and distribution data for inhaled candidates.
On-demand and scheduled asset-rating reports, competitive landscaping, second-opinion due diligence and expert medical opinions for investors.
Co-development of inhaler and nebulizer devices for administration of protein therapeutics, including integration of nebulization technology and transfer to industrial manufacturing capacity.
Outsourced development of industrial production processes for recombinant proteins, including analytical method development, upstream process optimization, technology transfer and cGMP manufacturing support through clinical and commercial scale-up.
End-to-end services covering preclinical proof-of-principle, IND-enabling study design, clinical trial preparation and regulatory submission support aimed at progressing candidates into proof-of-concept clinical trials.
Access to a network of scientific and clinical advisors in pulmonology, virology and aerosol medicine to inform translational strategy, target selection and trial design.
Preclinical testing services using lung-on-chip microphysiological systems combined with computational pulmonary distribution and aerosol deposition simulations to generate human-relevant safety and distribution data for inhaled candidates.
Expertise Areas
- Orthopedic trauma device design and fixation systems
- Implant materials and antibacterial surface technologies
- Clinical development and operations for devices and inhaled biologics
- Recombinant protein therapeutic discovery and preclinical development
Key Technologies
- Recombinant protein production using microbial and yeast expression systems
- Protein nebulization and inhalation delivery engineering
- Aerosol medicine and pulmonary deposition optimization
- Polyaxial locking plate-and-screw fixation systems
News & Updates
Nyxoah SA. received FDA approval for its Genio® System for the treatment of Obstructive Sleep Apnea.
Eckert & Ziegler SE announced a further increase in earnings in the first half of 2025.
CureVac announced the resolution of patent litigation with Pfizer/BioNTech.
Abivax announced that over 1,000 participants have been enrolled in the Phase 3 ABTECT clinical trial evaluating obefazimod for ulcerative colitis, reaching 82% of targeted enrollment.
The Phase 3 ABTECT trial has enrolled 1,003 of the targeted 1,224 participants, with results expected in Q3 2025.
Nyxoah SA. received FDA approval for its Genio® System for the treatment of Obstructive Sleep Apnea.
Eckert & Ziegler SE announced a further increase in earnings in the first half of 2025.
CureVac announced the resolution of patent litigation with Pfizer/BioNTech.
Abivax announced that over 1,000 participants have been enrolled in the Phase 3 ABTECT clinical trial evaluating obefazimod for ulcerative colitis, reaching 82% of targeted enrollment.
The Phase 3 ABTECT trial has enrolled 1,003 of the targeted 1,224 participants, with results expected in Q3 2025.